December 21, 2023 — No two ways about it. This has been a big year of milestones in obesity and health. We and many others are still processing what we have witnessed in these past 12 months. But one way to gain perspective is to look at 2023 stats for the posts on ConscienHealth that you, a wise group […]
July 15, 2023 — Four years ago, bimagrumab was a castoff from Novartis. That company had originally developed this monoclonal antibody for treating a rare muscle disease. But it failed spectacularly with disappointing results from a phase 2b study in 2016. That was a big disappointment, so it’s little wonder that Novartis walked away. Three years later, a glimmer […]
November 2, 2021 — Monday was quite an opening day for ObesityWeek 2021. Starting with the lived experience, the meeting then moved quickly into some serious science, clinical care, and policy discussions. But one of the most impressive sessions of the day gave us a “tour de force” of future options under development for obesity care. Our friend Mike […]
October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]
September 27, 2021 — It was an exciting possibility. At ObesityWeek 2019, Novartis scientist Laura Coleman presented fascinating results for an experimental drug, bimagumide, in obesity. In a phase 2 study, it yielded impressive improvements in body composition for people with obesity. It wasn’t just making people lose body fat. It helped them also gain muscle mass. Then, it […]
January 26, 2021 — Innovation in obesity care has come a long way. Back in 2010, Sanofi was smarting from the spectacular failure of rimonabant and big pharma was closing down research programs in obesity. But Novo Nordisk forged ahead with an ambitious program and now has a successful portfolio in obesity care to show for it. Nonetheless, we […]
June 19, 2020 — In pharmaceuticals, a one-trick pony is doomed to oblivion. Some companies have a big hit with a successful drug and then struggle to follow up with more innovation. So patents expire and sales dwindle. The company with one-trick innovation fades away. But with solid clinical trial results announced yesterday for two new drugs in obesity, […]
January 6, 2020 — It was a stunning and unique result that seemed to come out of nowhere at ObesityWeek late last year. A new drug, bimagrumab, yielded a 21 percent reduction in fat mass after 48 weeks. But lean body mass went up by 3.6 percent. This result is distinctly different from what usually happens in obesity treatment. […]
November 5, 2019 — Success begets success. That’s a core message we’re taking away from a late-breaking forum on emerging anti-obesity medicines. Pharmaceutical researchers reviewed an impressive range of innovations that promise to set a higher bar for effective obesity care. All of this came before ObesityWeek kicks into high gear today. Building Upon Success Mads Tang-Christensen opened the […]
